Marrow Angiogenesis-Associated Factors as Prognostic Biomarkers in Patients with Acute Myelogenous Leukaemia
Resource
BRITISH JOURNAL OF CANCER v.97 n.7 pp.877-882
Journal
BRITISH JOURNAL OF CANCER
Journal Volume
v.97
Journal Issue
n.7
Pages
877-882
Date Issued
2007
Date
2007
Author(s)
LEE, CHENG-YEH
TIEN, HWEI-FANG
HU, CHUNG-YI
CHOU, WEN-CHIEN
LIN, LIANG-IN
Abstract
Bone marrow (BM) neoangiogenesis plays an important role in acute myelogenous leukaemia (AML), and depends on the interplay of members of the vascular endothelial growth factor (VEGF) and angiopoietin (Ang) families. We determined the marrow levels of seven molecules associated with angiogenesis in 52 AML patients before chemotherapy and 20 healthy controls: VEGF-A, VEGF/ PlGF, VEGF-C, VEGF-D, Ang-1, Ang-2, and Tie-2. All the molecules were quantified using enzyme-linked immunosorbent assay ( ELISA). Comparing to normal controls, the marrow levels of VEGF/PlGF, Ang- 2, and Tie-2 were significantly higher, and those of VEGF-C and Ang -1 were significantly lower in the AML patients (P < 0.001). A total of 31 patients were further subjected to survival analysis. Patients with lower Tie-2 (< 26 ng ml(-1)) and Ang -2 levels (< 4500 pg ml(-1)) displayed a survival advantage( P = 0.037 and 0.042, respectively), same as patients with higher VEGF/ PlGF (>= 1 pg ml(-1)) and VEGF-D levels (>= 350 pg ml(-1 )) (P = 0.020 and 0.016, respectively). An angio- index ((Ang-2 x Tie- 2)/ ( VEGF/ PlGF x VEGF-D)) was established and multivariate Cox regression analysis revealed that patients with higher angio-index values (>= 50 ) displayed poor prognosis ( hazard ratio 5.91, 95% confidence interval 1.99 -17.56; P 0.001). The angio-index is closely associated with the clinical outcome of AML patients and may be valuable in disease prognosis.
Subjects
prognostic biomarker
AML
angiopoietin family
VEGF family